Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreYour world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreFor government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MORE
Explore potential scenarios that the U.S. healthcare industry could face post COVID-19, and the strategies for where and how to compete in this evolving landscape.
This interactive e-book aims to assist U.S. pharma companies by providing insights into the most likely paths and how they can adapt their businesses for the post-pandemic world.
There are several trends affecting how MedTech companies will go to market in 2023, but three of the most interesting and impactful are the expansion of Ambulatory Surgery Centers (ASCs), the increasing power of Value Analysis Committees (VACs), and the growing acceptance of digital communications among MedTech stakeholders.
As the Human Data Science company, we are committed to helping do what needs to be done to keep things moving healthcare forward. Patients must be treated. Trials must continue. Innovation and discovery must continue – not just to solve our current crisis but also to ensure we are ready to take on what comes next.
